FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062776278> ?p ?o ?g. }

• W2062776278 endingPage "63" @default.
• W2062776278 startingPage "63" @default.
• W2062776278 abstract "Certolizumab in the long-term treatment of rheumatoid arthritis Abdul Khan, David L ScottDepartment of Rheumatology, King’s College London School of Medicine, King’s College, London, UKAbstract: Rheumatoid arthritis is the most common inflammatory arthritis and continues to have major long-term effects on quality of life. Early and intensive treatment has now become the norm in clinical practice with changes of medication dictated by measuring the presence of continued disease activity. Biologics, particular tumor necrosis factor inhibitors, have a crucial role in the management of very severe disease. Certolizumab is a relatively new tumor necrosis factor inhibitor which uses a novel strategy to neutralize TNF-alpha – the conjugation of tumor necrosis factor specific Fab antibody fragments to polyethylene glycol. Two Phase II and three Phase III randomized controlled trials have evaluated the efficacy and toxicity of certolizumab. More than 2000 patients were enrolled, and followed from 12–52 weeks. The number of patients achieving significant improvements with certolizumab, was indicated by the American College of Rheumatology with a 50% response rate. The risk ratios of achieving this response at 24 weeks was 6.01 (95% confidence interval [CI]: 3.84–9.40). At 52 weeks the risk ratio was 5.27 (95% CI: 3.19–8.71). The number of patients needed to treat, to obtain this benefit at 24 weeks was 4 (95% CI: 3–5). Certolizumab also had important clinical benefits in reducing erosive damage to joints, limiting disability, and enhancing other outcomes of importance to patients such as fatigue. The patient-related benefits were present from the early weeks of treatment. The clinical trials showed serious adverse events, including infections, which were more frequent for certolizumab. The most common adverse events comprised upper respiratory tract infections, hypertension, and nasopharyngitis. The balance of evidence suggests that certolizumab is equivalent to other tumor necrosis factor inhibitors, though no head-to-head trials have been undertaken. Having several effective treatments available, benefits patient choice, because the frequency and route of administration of these treatments varies. Furthermore, as intolerance and antibody development against existing biologics is not uncommon, having several agents allows opportunities to switch from one inhibitor to another.Keywords: rheumatoid arthritis, certolizumab, anti-TNF" @default.
• W2062776278 created "2016-06-24" @default.
• W2062776278 creator A5050928134 @default.
• W2062776278 creator A5090444972 @default.
• W2062776278 date "2011-08-01" @default.
• W2062776278 modified "2023-10-16" @default.
• W2062776278 title "Certolizumab in the long-term treatment of rheumatoid arthritis" @default.
• W2062776278 cites W1601972531 @default.
• W2062776278 cites W1701993624 @default.
• W2062776278 cites W1867131794 @default.
• W2062776278 cites W1969420519 @default.
• W2062776278 cites W1996373258 @default.
• W2062776278 cites W1996389186 @default.
• W2062776278 cites W1999777294 @default.
• W2062776278 cites W2006566716 @default.
• W2062776278 cites W2014709373 @default.
• W2062776278 cites W2018645348 @default.
• W2062776278 cites W2045610497 @default.
• W2062776278 cites W2046540088 @default.
• W2062776278 cites W2065344034 @default.
• W2062776278 cites W2067717482 @default.
• W2062776278 cites W2072738451 @default.
• W2062776278 cites W2079759594 @default.
• W2062776278 cites W2089242190 @default.
• W2062776278 cites W2092063686 @default.
• W2062776278 cites W2099199787 @default.
• W2062776278 cites W2104902789 @default.
• W2062776278 cites W2106964599 @default.
• W2062776278 cites W2116996289 @default.
• W2062776278 cites W2124243366 @default.
• W2062776278 cites W2125759824 @default.
• W2062776278 cites W2137454541 @default.
• W2062776278 cites W2137592803 @default.
• W2062776278 cites W2139472802 @default.
• W2062776278 cites W2143839327 @default.
• W2062776278 cites W2146455486 @default.
• W2062776278 cites W2152348310 @default.
• W2062776278 cites W2154515402 @default.
• W2062776278 cites W2163817180 @default.
• W2062776278 cites W2166732840 @default.
• W2062776278 cites W2168711492 @default.
• W2062776278 cites W2206746226 @default.
• W2062776278 cites W2302652017 @default.
• W2062776278 cites W2337465401 @default.
• W2062776278 cites W2340084730 @default.
• W2062776278 cites W4210968471 @default.
• W2062776278 cites W4302605281 @default.
• W2062776278 cites W60457073 @default.
• W2062776278 doi "https://doi.org/10.2147/oarrr.s14556" @default.
• W2062776278 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5074781" @default.
• W2062776278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27790005" @default.
• W2062776278 hasPublicationYear "2011" @default.
• W2062776278 type Work @default.
• W2062776278 sameAs 2062776278 @default.
• W2062776278 citedByCount "2" @default.
• W2062776278 countsByYear W20627762782012 @default.
• W2062776278 countsByYear W20627762782013 @default.
• W2062776278 crossrefType "journal-article" @default.
• W2062776278 hasAuthorship W2062776278A5050928134 @default.
• W2062776278 hasAuthorship W2062776278A5090444972 @default.
• W2062776278 hasBestOaLocation W20627762781 @default.
• W2062776278 hasConcept C126322002 @default.
• W2062776278 hasConcept C141071460 @default.
• W2062776278 hasConcept C1862650 @default.
• W2062776278 hasConcept C198451711 @default.
• W2062776278 hasConcept C2776215756 @default.
• W2062776278 hasConcept C2777575956 @default.
• W2062776278 hasConcept C2780132546 @default.
• W2062776278 hasConcept C71924100 @default.
• W2062776278 hasConceptScore W2062776278C126322002 @default.
• W2062776278 hasConceptScore W2062776278C141071460 @default.
• W2062776278 hasConceptScore W2062776278C1862650 @default.
• W2062776278 hasConceptScore W2062776278C198451711 @default.
• W2062776278 hasConceptScore W2062776278C2776215756 @default.
• W2062776278 hasConceptScore W2062776278C2777575956 @default.
• W2062776278 hasConceptScore W2062776278C2780132546 @default.
• W2062776278 hasConceptScore W2062776278C71924100 @default.
• W2062776278 hasLocation W20627762781 @default.
• W2062776278 hasLocation W20627762782 @default.
• W2062776278 hasLocation W20627762783 @default.
• W2062776278 hasLocation W20627762784 @default.
• W2062776278 hasOpenAccess W2062776278 @default.
• W2062776278 hasPrimaryLocation W20627762781 @default.
• W2062776278 hasRelatedWork W2045151582 @default.
• W2062776278 hasRelatedWork W2082406232 @default.
• W2062776278 hasRelatedWork W2156283049 @default.
• W2062776278 hasRelatedWork W230393467 @default.
• W2062776278 hasRelatedWork W2316954211 @default.
• W2062776278 hasRelatedWork W2326094713 @default.
• W2062776278 hasRelatedWork W2427075784 @default.
• W2062776278 hasRelatedWork W2617939361 @default.
• W2062776278 hasRelatedWork W2761967325 @default.
• W2062776278 hasRelatedWork W4210646529 @default.
• W2062776278 isParatext "false" @default.
• W2062776278 isRetracted "false" @default.
• W2062776278 magId "2062776278" @default.
• W2062776278 workType "article" @default.